Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Tislelizumab + GCS in Resectable High-Risk iCCA
NCT06903273Phase 2Not yet recruiting
- Sponsor
- National Cheng Kung University Hospital
- Start
- Jul 2025
- Primary completion
- Jul 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in intrahepatic cholangiocarcinoma (ICC), sponsored by National Cheng Kung University Hospital. Primary endpoint: R0 Resection Rate at 2 weeks. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT06903273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06903273.